Amyotrophic Lateral Sclerosis (ALS) News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Discovery of a promising medication for amyotrophic lateral sclerosis (ALS) - Science Daily



Science Daily
 
Discovery of a promising medication for amyotrophic lateral sclerosis (ALS) 
Science Daily
The two scientists obtained funding from the U.S. Department of Defense to test medications on these worms and fish born with ALS. "We sifted through a library of 3,850 molecules approved for the treatment of other diseases, and found a class of ...

 


Preclinical Data Supporting Wave Life Sciences ALS and FTD Programs Presented at 28th International Symposium on ... - GlobeNewswire (press release)



Dispatch Tribunal
 
Preclinical Data Supporting Wave Life Sciences ALS and FTD Programs Presented at 28th International Symposium on ... 
GlobeNewswire (press release)
CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced data from ...
WAVE LIFE SCIENCES LTD. (NASDAQ:WVE) Files An 8-K Regulation FD Disclosure Market Exclusive

all 25 news articles » 


Dying Of ALS, Sam Shepard Told His Final Story Of A Man Not Ready To Go - WBUR



WBUR
 
Dying Of ALS, Sam Shepard Told His Final Story Of A Man Not Ready To Go 
WBUR
Sam Shepard once said, "I could go on and on about death. One of my favorite subjects ? so long as you can keep it at arm's length." Death came for Shepard this past summer, when at age 73 the renowned actor and playwright succumbed to amyotrophic ...

 


Before 40, Brain Atrophy in ALS Mutation Carriers? - Alzforum



Alzforum
 
Before 40, Brain Atrophy in ALS Mutation Carriers? 
Alzforum
Long before outward signs of neurodegenerative disease, carriers of a hexanucleotide expansion in the C9ORF72 gene already have changes in their brains, according to new research. In the December 2 JAMA Neurology, researchers led by Isabelle Le Ber at ...

 


Roper St. Francis Foundation receives large donation to find a cure for Lou Gehrig's disease - Charleston Post Courier



Charleston Post Courier
 
Roper St. Francis Foundation receives large donation to find a cure for Lou Gehrig's disease 
Charleston Post Courier
The Roper St. Francis Foundation recently received the largest gift in its 12-year history ? a $1.5 million donation, with $500,000 more to come, for the purpose of "finding a cause and cure" for amyotrophic lateral sclerosis, commonly called ALS ...

and more » 


Medicinova (MNOV) MN-166 Trial in ALS Met Primary Safety and Tolerability Endpoint - StreetInsider.com



Medicinova (MNOV) MN-166 Trial in ALS Met Primary Safety and Tolerability Endpoint 
StreetInsider.com
MediciNova, Inc., (NASDAQ: MNOV) today announced positive top-line results from MediciNova's clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS). Data analysis was conducted on the 51 subjects without non-invasive ventilation in ...

and more » 


MediciNova Announces Positive Top-Line Results From The Clinical Trial Of MN-166 (ibudilast) In ALS - Clinical Leader



MediciNova Announces Positive Top-Line Results From The Clinical Trial Of MN-166 (ibudilast) In ALS 
Clinical Leader
La Jolla, CA (GLOBE NEWSWIRE) - MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive top-line results from ...

 


A treatment for ALS just failed a key clinical trial - Business Insider



Forbes
 
A treatment for ALS just failed a key clinical trial 
Business Insider
Nov 21 (Reuters) - Cytokinetics Inc will stop developing one of its treatments for ALS, which afflicts Stephen Hawking, after the drug failed in a late-stage trial, the company said on Tuesday, sending its shares tumbling about 35 percent. The ...
Cytokinetics ALS Drug Fails Forbes
Cytokinetics Pivots to Another ALS Drug After Phase 3 Failure Xconomy
Cytokinetics cans lead drug after phase 3 ALS wipeout FierceBiotech
GlobeNewswire (press release)  -BioPharma Dive  -Pharmaceutical Processing  -Zacks.com 
all 124 news articles » 


EEG and MRI combined help shed light on ALS: FIndings imply that ... - Science Daily



EEG and MRI combined help shed light on ALS: FIndings imply that ... 
Science Daily
Researchers have been studying brain wave patterns in the neurodegenerative condition amyotrophic lateral sclerosis (ALS). They have made the surprising discovery that some specific parts of the brain are 'over-connected' in ALS, while other parts show ...

and more » 


Auburn's man of sole: Pacin' Parson walks for ALS - Auburn Reporter



Auburn Reporter
 
Auburn's man of sole: Pacin' Parson walks for ALS 
Auburn Reporter
... according to the National Institute of Neurological Disorders and Stroke, and most people with the disease die from respiratory failure within 3 to 5 years of symptoms first appearing. Amyotrophic Lateral Sclerosis was discovered in 1869 but was ...